These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32590336)

  • 1. The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors.
    Takkenkamp TJ; Jalving M; Hoogwater FJH; Walenkamp AME
    Endocr Relat Cancer; 2020 Sep; 27(9):R329-R343. PubMed ID: 32590336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumours and their microenvironment.
    de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
    Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of immune microenvironment in gastrointestinal stromal tumours.
    Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
    Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
    Xu G; Wang Y; Zhang H; She X; Yang J
    Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
    Li Z; Deng J; Sun J; Ma Y
    Front Immunol; 2020; 11():595207. PubMed ID: 33240283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
    Engin AB; Engin A
    Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
    Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
    Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
    Oladejo M; Paulishak W; Wood L
    Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
    Hou A; Hou K; Huang Q; Lei Y; Chen W
    Front Immunol; 2020; 11():783. PubMed ID: 32508809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma.
    Chinnadurai R; Scandolara R; Alese OB; Arafat D; Ravindranathan D; Farris AB; El-Rayes BF; Gibson G
    Front Oncol; 2020; 10():1632. PubMed ID: 33014820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tryptophan metabolism in cancers and therapeutic implications.
    Liu XH; Zhai XY
    Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
    Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
    Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
    Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Fazio N; Abdel-Rahman O
    Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
    Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
    Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.